NICE Conference 2026 presentations
Add text from NICE
Smoothing the pathway to adoption
How does NICE work with partners to balance speedy access to innovation, while also considering significant pressures across the health and care system and the need to reduce health inequalities? How do we smooth the pathway to bring new technologies and solutions to the NHS that meet unmet clinical needs?
Driving access to transformative treatments and supporting a thriving life sciences industry
Find out how NICE is committed to helping position the NHS as a powerful customer for life sciences – one of the UK’s fastest growing industries. Hear about how NICE’s evaluation approaches are evolving to ensure a transparent, predictable and timely service for companies, patients and the NHS.
Weighing up the evidence: Behind the scenes at NICE
Take a look behind the scenes at how NICE makes decisions. How is evidence considered, recommendations developed and what does good look like? How do we ensure that the voices of patients and those with lived experience are heard? How has the process evolved over the years and how are we ensuring our methods remain at the global forefront of technology evaluation and guideline development?
International collaboration to develop health technology assessment methods
Find out how NICE is working with international partners to critically and independently research some of the most pressing topics in global health decision making. Discover how NICE is exploring whether additional benefits – beyond increased life expectancy and quality of life – should be captured in the evaluation of new medicines and health technologies, in partnership with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC). Hear directly from those involved about the role the new Health Economics Methods Advisory (HEMA) group will play in examining new health technology assessment (HTA) methods.
Driving NHS reform through innovation and value
The message in the 10 Year Health Plan is clear – the NHS must reform if it is to survive. There is a real drive to put patients and local services at the heart of its recovery, and to provide more convenient care in people’s neighbourhoods. How is NICE helping commissioners and providers get the care to patients fast, at a time of increased financial and workforce pressures? Could digital technologies, genomics and the introduction of biosimilars be routes to success? Does NICE need to do more to update and decommission guidance where new evidence shows there is a better way?
Supporting effective decision making: Delivering more usable NICE guidance
How is NICE supporting health and care practitioners, commissioners and providers to make decisions more easily using its guidance? What is being done to improve the usability of NICE guidance and reimagine products that better meet our users’ needs? How is NICE collaborating to make the most of technological innovation, artificial intelligence and data to help users easily find the information they need, when they need it?
In the spotlight: A unique partnership to address health inequalities
Reducing health inequalities is part of NICE’s DNA – achieving fair outcomes is central to the advice we provide. This year, NICE embarked on a groundbreaking new partnership with the NHS Race and Health Observatory in a bid to tackle persistent and systemic ethnic health inequalities. What has been achieved so far? What more needs to be done? How can we learn from this approach to help address other areas of health inequalities?
International collaboration to develop health technology assessment methods
Find out how NICE is working with international partners to critically and independently research some of the most pressing topics in global health decision making. Discover how NICE is exploring whether additional benefits – beyond increased life expectancy and quality of life – should be captured in the evaluation of new medicines and health technologies, in partnership with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC). Hear directly from those involved about the role the new Health Economics Methods Advisory (HEMA) group will play in examining new health technology assessment (HTA) methods.
Closing the loop: NICE's role in building a learning healthcare system
Most people agree the concept of a continually learning healthcare system is desirable, but the concept hasn’t really taken off yet. What is NICE’s role in bringing about this step change? How can it lead the way in learning from data and implementation?
Improving uptake and adoption
Health and care decisions are made at different levels across the system. Discover how NICE is working with commissioners, practitioners and providers on to improve the uptake and adoption of guidance. Hear how the approach is being used to support the role out of a new generation drugs with the potential to treat large numbers of people. Explore how NICE is contributing to a learning health system, using data and intelligence to understand uptake, barriers and the enablers that drive continuous improvement.
A strengthened role for NICE in driving value and maximising population health: A whole lifecycle approach to developing and maintaining guidance
The 10 Year Health Plan strengthens NICE’s role in driving better value by continually re-evaluating clinical pathways. Discover how a whole lifecycle approach to guidance production will enable us to expand access to cost-effective innovations, provide clearer decision pathways for clinicians, and phase out less effective innovations to create financial headroom for tomorrow’s breakthroughs.